EXPRESSION OF A PUBLIC IDIoTYPE BY HUMAN MONOCLONAL IgM DIRECTED TO MYELIN-ASSOCIATED GLYCOPROTEIN AND CHARACTERIZATION OF THE VARIABILITY SUBGROUP OF THEIR HEAVY AND LIGHT CHAINS

By JEAN-CLAUDE BROUET, KOUSSAY DELLAGI, MARIE-CLAUDE GENDRON, ANNETTE CHEVALIER, CHRISTIAN SCHMITT, AND EDITH MIHAESCO

From the Laboratory of Immunochemistry and Immunopathology, Institut National de la Santé et de la Recherche Médicale, Unité 108, Hôpital Saint-Louis, 75010 Paris, France

Since the pioneering work of Kunkel et al. (1, 2), a number of studies established that human monoclonal IgM with a defined antibody activity such as rheumatoid factors (RF) (1) or cold agglutinins (CA) share crossreactive idiotopes (CRI).

In sharp contrast, it has been exceedingly difficult to obtain antiidiotypic reagents defining CRI on human monoclonal IgM reactive with myelin-associated glycoprotein (MAG). Whereas most studies yielded reagents that only defined private idiotopes on the immunizing IgM (3–6), we and others have previously shown that a restricted set of anti-MAG IgM shared CRI defined by a small subset of antibodies from rabbit antiidiotypic sera (7) or by mouse mAbs (8). The lack of broadly distributed CRI is not related to an heterogeneity of the fine specificity of these IgM since several studies indicate that most if not all react with a glucuronyl sulfated epitope carried by MAG and a peripheral nerve glycolipid, the sulfated 3-glucuronyl paragloboside (SGPG) (9, 10).

We report here the characterization, by a primate serum to human anti-MAG IgM, of combining site-related idiotope(s) shared by 9 of 10 IgM, and the assignment of light and heavy chains of 7 of these IgM to Ig variable subgroups as defined by their NH2-terminal amino acid sequence.

Materials and Methods

Monoclonal IgM to MAG. Sera were obtained from 10 patients with monoclonal IgM and peripheral neuropathy. The specificity of the monoclonal IgM was assessed by immunoblotting analysis on human central nervous system myelin polypeptides. For some experiments,
MAG was prepared from delipidated myelin by lithium diodosaliclylate and phenol extraction according to Quarles and Pasnak (11).

**Partial NH₂-Terminal Sequence of IgM Heavy and Light Chains.** Monoclonal IgM were isolated from sera by 40% saturated ammonium sulfate precipitation and were purified by gel chromatography followed by preparative zone electrophoresis. IgA, IgG, haptoglobin, and transferrin contaminants were removed on affinity adsorbsents. Heavy and light chains were obtained by mild reduction performed with 10 mM 1,4-dithio-Dl-threitol and alkylation with 10% excess of [14C]iodoacetic acid (7.5. 10⁶ cpm/mol) (Amersham Corp., Amersham, UK); thereafter the chains were separated on a Sephadex G100 column equilibrated with 1 M acetic acid. The typing of variable regions from heavy and light chains was achieved by Edman sequence degradation, using 4N,N'-dimethylaminobenzene-4-isothiocyanate (Fluka, Buchs, Switzerland)/phenyl-isothiocyanate (Pierce Chemical Co., Rockford, IL) double-coupling method followed by thin-layer chromatography (12).

**Antiidiotypic Serum.** An adult marmoset was injected with purified IgMROG; the first immunization was performed subcutaneously in IFA (500 µg IgM in multiple sites) and booster injections were given every 15 d with IgMROG resuspended in saline buffer. Bleedings were obtained at monthly intervals and tested by double immunodiffusion against a panel of monoclonal anti-MAG IgM and normal serum. Bleedings that reacted strongly with anti-MAG IgM but not or weakly with normal serum were pooled and absorbed on Sepharose 4B beads coupled to normal human serum, polyclonal IgG, or four different monoclonal IgM devoid of anti-MAG specificity. This marmoset antiidiotypic serum was thereafter studied by ELISA.

**ELISA Assays.** The reactivity of marmoset antiidiotypic serum with anti-MAG or normal IgM was assessed by two ELISA assays. First, microtiter plates (Consortium de Materiel pour Laboratoire, Nemours, France) coated with 1 µg IgM/well for 18 h were blocked with 3% BSA in saline and incubated with serial dilutions of marmoset antiidiotypic serum; the binding of marmoset IgG was revealed with β-galactosidase-labeled goat antibodies to human IgG (Biosys, Compiègne, France) followed by substrate. No reactivity was recorded when the addition of marmoset antiidiotypic was omitted or when nonimmune marmoset serum was used. A similar assay was performed on plates coated with 10 µg/well of purified μ, κ, or λ chains.

Alternatively, monoclonal IgM were incubated for 12 h on plates precoated with 1 µg/well of mouse mAb to μ heavy chain. Thereafter, marmoset antiidiotypic antibody was added at a 10⁻¹ dilution and the assay was developed with phosphatase alkaline-conjugated purified goat IgG to human (and primate) γ chains (Caltag Laboratory, San Francisco, CA) absorbed on mouse Ig, followed by substrate.

Inhibition experiments were performed as follows: anti-μ precoated plates were incubated with 5 µg/well IgMDEP and revealed by marmoset antiidiotypic antibody (1/30 final dilution) previously incubated for 12 h with various amounts (10⁻² to 10² µg) of anti-MAG or of an irrelevant monoclonal IgM followed by phosphatase alkaline-conjugated purified goat antibodies to human γ chains and substrate.

In other experiments, glutaraldehyde-pretreated plates were incubated with 10 µg of purified MAG, blocked with 1-lysine and various amounts of anti-MAG IgM previously incubated for 18 h with a 1/50 final dilution of marmoset antiidiotypic serum were added. Plates were revealed with β-galactosidase-labeled goat antibodies to human μ chains followed by substrate (Biosys).

**Results**

**Specificity of Marmoset Antiidiotypic Serum.** As evidenced by immunoblotting experiments, the 10 IgM studied reacted with 90/100-kD polypeptides of myelin corresponding to MAG. In addition, IgM bound to purified MAG by immunoblotting or ELISA assays (not shown).

As shown in Fig. 1, 9 of 10 anti-MAG IgM reacted with marmoset antiidiotypic serum in two different assays. The immunizing IgMROG always yielded the highest optical densities, whereas IgMLoc gave only background values similar to that ob-
Gallinules antitoxic serum with 10 anti-MAG IgM (closed symbols), irrelevant IgM (open symbols), or isolated heavy and light chains in ELISA. (A) Direct binding using serial dilutions of marmoset antitoxic serum. (B) IgM were captured on anti-μ-coated plates before addition of a 10⁻¹ dilution of marmoset antitoxic serum (See Methods).

served with irrelevant monoclonal IgM. Inhibition studies confirmed the existence of crossidiotopes between IgM (Fig. 2 A) since the fixation of marmoset antitoxic serum to IgMDEP (i.e., an IgM different from that used for immunization) was completely inhibited in the presence of anti-MAG IgM studied but was unaffected by an irrelevant IgMLEC.

At least some of the shared idiotopes appeared to be related to the combining site of the IgM since incubation of four IgM with marmoset antitoxic serum inhibited their binding to MAG by ELISA (Fig. 2 B). In similar experiments, rabbit antisera to anti-MAG IgM that recognized private or semipublic idiotopes were not inhibitory (7; and unpublished data).

Marmoset antitoxic serum did not react either with isolated heavy and light chains from the six anti-MAG IgM tested or with variable subgroup matched μ chains or purified light chains (Fig. 1 B). Finally, various marmoset bleedings were tested by fluorescence on nerve sections for the presence of anti-antiidiotypic (ab3) antibodies: none were found, even in late bleedings after the end of booster immunizations.

NH₂-Terminal Sequence of Heavy and Light Chains of Anti-MAG IgM. Of seven IgM studied, only one possessed λ chains (AZI) with a VH₃ variable region. Three κ chains (DEP, FUE, and LOC) belonged to the V₄IV subgroup with characteristic amino acids at position 9 and 12 (13). Two κ chains (BOU and BLA) were assigned to the V₄ subgroup, although several mutations existed in comparison to prototype sequence (Table I) since they had the relatively invariant amino acids of V₄ subgroup at position 3 and 13 and none of the characteristic amino acids of the other subgroups. Finally, IgM PEC belonged to the V₁ subgroup as shown by its NH₂-terminal sequence and the finding of an invariant methionine at position 89. Heavy chain NH₂-terminal amino acid sequence allowed the assignment to the V₁ subgroup of 6 μ chains whose 10 first residues were identical to that of the V₁Gal prototype sequence (13). IgM AZI belonged to the V₁ subgroup with a single
FIGURE 2. Shared idiotype(s) between anti-MAG IgM are combining site-related. (A) Anti-MAG IgM_{ROG}, DEP, YSR, ROU, PEC, but not irrelevant IgM_{LEC}, inhibit the binding of marmoset antidiotopic serum to IgM_{DEP}-coated plates (see Materials and Methods). (B) Inhibition of binding of various concentrations of IgM_{ROG} (■), DEP (○), ROU (▲), PEC (△) to MAG-coated plates by a 1/50 dilution of marmoset antidiotopic serum. Closed symbols represent optical density at 405 nM without serum and open symbols with marmoset antidiotopic serum.
TABLE I

NH₂-Terminal Sequence of seven Anti-MAG IgM Light Chains Compared with that of Prototype Sequence of Variability Subgroups

<table>
<thead>
<tr>
<th>Protein</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
</tr>
</thead>
<tbody>
<tr>
<td>V₄₄ SCW</td>
<td>D</td>
<td>I</td>
<td>Q</td>
<td>M</td>
<td>T</td>
<td>Q</td>
<td>S</td>
<td>P</td>
<td>S</td>
<td>S</td>
<td>L</td>
<td>S</td>
<td>A</td>
</tr>
<tr>
<td>IgM BOU</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>T</td>
<td>T</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IgM BLA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>T</td>
<td>T</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>V₄₄ TEW</td>
<td>D</td>
<td>I</td>
<td>V</td>
<td>M</td>
<td>T</td>
<td>Q</td>
<td>S</td>
<td>P</td>
<td>L</td>
<td>S</td>
<td>L</td>
<td>P</td>
<td>V</td>
</tr>
<tr>
<td>IgM PEC</td>
<td>-</td>
<td>V</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>V</td>
<td>T</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>V₄₅ LEN</td>
<td>D</td>
<td>I</td>
<td>V</td>
<td>M</td>
<td>T</td>
<td>Q</td>
<td>S</td>
<td>P</td>
<td>N</td>
<td>S</td>
<td>L</td>
<td>A</td>
<td>V</td>
</tr>
<tr>
<td>IgM DEP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>E</td>
<td>-</td>
<td>-</td>
<td>E</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IgM FUE</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>E</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IgM LOC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>V₄₅ NEI</td>
<td>PCA</td>
<td>S</td>
<td>A</td>
<td>L</td>
<td>T</td>
<td>Q</td>
<td>P</td>
<td>A</td>
<td>S</td>
<td>V</td>
<td>S</td>
<td>G</td>
<td>S</td>
</tr>
<tr>
<td>IgM AZI</td>
<td>L</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>P</td>
<td>-</td>
<td>-</td>
<td>T</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* Amino acids are designated by the single letter code. Only deviations from the prototype are shown.

...amino acid substitution at position 7 (threonine for serine) when compared with the OU prototype sequence.

Discussion

Monoclonal IgM directed to MAG and nerve glycolipids recently attracted much interest since they may mediate the first instance of human autoimmune peripheral neuropathy. Although this matter remains controversial, intraneural injections of anti-MAG IgM as well as passive transfer experiments support this possibility (reviewed in reference 14). So far the antigenic and biochemical features of these IgM remain poorly characterized.

We show here that a primate antiserum to human anti-MAG IgM contains antibodies to a combining site-related public crossidiotypic carried by 9 of 10 IgM tested. This antiserum was able to block the binding of monoclonal IgM to MAG and reacted with several IgM having κ or λ chains and μ heavy chain belonging to VH₃ (all IgM κ) or VH₃ (one IgM λ) subgroups. In addition, inhibition studies suggested that all reactive IgM share a similar set of idiotopes. This marmoset antiidiotypic serum most likely recognizes conformational epitope(s) since it was unreactive with isolated light and heavy chains. These results contrast with those from previous reports where only private or highly restricted idiotypes were disclosed by rabbit polyclonal antisera and mouse mAbs antibodies (3-8; and unpublished data). The reasons for this discrepancy are not readily apparent. Of note, mouse and rabbit MAG are unreactive with human anti-MAG IgM and possibly the repertoire of these animals is submitted to idiotypic regulation depending on the structure of self antigens. Such species-restricted ab2 response have already been observed for RF (15). On the other hand, structural data (see below) showed that the combining site of these IgM is most often composed of VH₃-related heavy chains paired with κ chains belonging to different subgroups of variability. Therefore, epitopes exposed at the surface of the IgM and that are immunogeneic in these species may be different from one IgM...
to the other. In either instance, more related species, such as nonhuman primates, could more easily recognize human anti-MAG IgM combining sites. That such broadly crossreactive antiidiotypic antibodies are mostly directed against epitope(s) involved in (or close to) the combining site is not unexpected in view of the highly restricted specificity of anti-MAG IgM for a glucuronyl sulfated epitope of the carbohydrate moiety of MAG and peripheral nerve glycolipid SGPG (9, 10). However, slight differences in the fine specificity of anti-MAG IgM may exist (16, 17), and could account for the variable levels of binding to marmoset antiidiotypic serum of different anti-MAG IgM.

Dissection of the antigenic and structural relationship between individual monoclonal RF or CA in humans revealed that only a limited number of germline genes undergoing relatively few somatic mutations contribute to the generation of these monoclonal antibodies (18–20). Strikingly, a majority of monoclonal RF or CA possess light chains belonging to the V_{HIII} subgroup. Most of them derive from a single (Hum 325) or closely related variable κ genes. Since other autoantibodies use also V_{kHIII}-related genes (21), a model for autoantibody generation has been proposed where the binding specificity is defined by the variable segment of heavy chains paired with multipotential light chains (18). Obviously anti-MAG IgM do not fit within this scheme; light chains from these IgM indeed belong to different V_{κ} variability subgroups (V_{κIβ}, V_{κII}, V_{κIV}) and none are related to the V_{κHIII} subgroup so far. Interestingly half of the κ chains studied belong to the rare V_{κIV} subgroup, which is associated with <5% of sequenced light chains and coded by a single germline V_{κIV} gene.

These various light chains of anti-MAG were associated in all but one instance to V_{HIII}-derived μ heavy chains. Such a restriction of heavy chain variable regions is consistent with previous data for both RF and CA. However, at least three different V_{H} variable genes are used by the RF belonging to the Wa CRI group and limited structural studies showed that salient features were the use of a J_{H4} region and of D_{H} regions of uniform size (22). Therefore, more structural data are needed to attain meaningful conclusions.

Altogether the present results indicate that anti-MAG IgM exhibit distinct antigenic and structural features as compared with those of other monoclonal IgM with a defined antibody activity. Whether or not they correspond to different pathogenetic processes (antigen-driven autoantibodies versus spontaneous production of autoantibodies from germline genes with few somatic mutations) presently remains speculative.

Summary

Most studies using rabbit or mouse antisera failed to detect CRI between human IgM directed to MAG. We show here that 9 of 10 such IgM express a public CRI as defined by a nonhuman primate antisera. Shared idiotype is likely involved in (or close to) the combining site of those IgM since antiidiotypic serum inhibited the binding of IgM to MAG and reacted with IgM having different variable regions of light and heavy chains. Partial aminoterminal sequence of heavy and light chains showed that anti-MAG IgM use either λ chains (one IgM) or κ light chains (six IgM) of different variability subgroups (V_{κIV} in three instances, V_{κI} in two, and V_{κII} in one), whereas heavy chains belong to the V_{HIII} (six IgM) or to the V_{HII} (1 IgM)
subgroup. These features distinguish these IgM from other human monoclonal IgM with a defined antibody activity, such as rheumatoid factors or cold agglutinins.

We are indebted to C. Mihaesco and G. Mahouy for their help in various aspects of this study. We thank Professor M. Seligmann for helpful discussion and review of the manuscript. The assistance of Jacqueline LaPerriere in the preparation of IgM and of Marie-Thérèse Miglierina in typing the manuscript is gratefully acknowledged.

Received for publication 5 May 1989 and in revised form 28 June 1989.

References